Nascent Biotech, Inc.

Equities

NBIO

US63108Q1013

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:14:22 2024-06-06 EDT			5-day change	1st Jan Change
0.0969 ^USD	+7.67%		-1.62%	-43.96%

04-16	Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	CI
03-19	Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab	CI

Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022

June 15, 2022 at 03:37 pm

Nascent Biotech, Inc. reported earnings results for the full year ended March 31, 2022. For the full year, the company reported sales was USD 1 million compared to USD 0.75 million a year ago. Net loss was USD 0.47039 million compared to USD 0.958767 million a year ago.

Latest news about Nascent Biotech, Inc.

Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	04-16	CI
Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab	03-19	CI
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Nascent Biotech and Manhattan Biosolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates	02-06	CI
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer	23-08-22	CI
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-18	CI
Nascent Biotech, Inc. Auditor Raises 'Going Concern' Doubt	23-07-02	CI
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-29	CI
Nastcent Biotech, Inc. and BioRay Pharmaceutical Co Mutually Terminates the License Agreement	23-05-30	CI
Nascent Biotech, Inc. Announces the Completion of Its Phase1 Clinical Trials	23-02-28	CI
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial	23-01-25	CI
Nascent Biotech, Inc. Enrolls Final Patient Cohort in Phase I Brain Cancer Trial	23-01-10	CI
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board	22-12-20	CI
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-10	CI
Nascent Biotech, Inc. Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research	22-10-04	CI
Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer	22-09-13	CI
Nascent Biotech, Inc. announced that it has received $0.2425 million in funding from Platinum Point Capital LLC	22-09-07	CI
Nascent Biotech, Inc. announced that it expects to receive $1.5 million in funding from Yorkville Advisors Global LP	22-08-29	CI
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-09	CI
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-15	CI
Nascent Biotech, Inc. Auditor Raises 'Going Concern' Doubt	22-06-14	CI
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-04	CI

Chart Nascent Biotech, Inc.

Duration

Period

More charts

Company Profile

Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. Its initial focus is on patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. The Company is exploring Pritumumab in its use against viruses. The Company is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NASCENT BIOTECH, INC.	-43.96%	16.53M
VERTEX PHARMACEUTICALS INCORPORATED	+19.33%	125B
REGENERON PHARMACEUTICALS, INC.	+13.95%	108B
BIONTECH SE	-3.53%	24.57B
ARGENX SE	+2.71%	22.82B
GENMAB A/S	-9.95%	18.19B
WUXI APPTEC CO., LTD.	-41.48%	16.54B
BEIGENE, LTD.	-12.62%	16.5B
NEUROCRINE BIOSCIENCES, INC.	+0.99%	13.39B
SAREPTA THERAPEUTICS, INC.	+21.79%	11.1B

Bio Therapeutic Drugs